USSTOCK.TODAY
Market Closed
Log in Sign up

Ultragenyx Pharmaceutical sells rare pediatric disease priority review voucher for $210 million

Stocktwits +1 ·

RARE
RARE Ultragenyx Pharmaceutical Inc
$15.48 +1.24%
View chart & analysis →
  1. 1Ultragenyx Pharmaceutical has agreed to sell a rare pediatric disease priority review voucher for $210 million.
  2. 2RARE shares rose 4% at the time of writing.
  3. 3This transaction marks the third voucher sale following Ultragenyx's previous two sales totaling $210.6 million in 2018.

So what's the key point?

Ultragenyx Pharmaceutical sold the right to receive an expedited review for a rare disease treatment. The company's stock price rose 4% following this deal.

Source Stocktwits +1 · View original ↗

Related 3-line summaries

Ultragenyx shares plunge 44.7% premarket after GTX-102 Phase 3 failure InvestorsHub +1 · Sep 3MongoDB(MDB) shares slide ~15% despite strong earnings GuruFocus.com +3 · Sep 2SK Hynix to buy back and cancel 40 trillion won worth of treasury shares, strengthening shareholder returns Reuters +4 · Aug 19
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news